美国Entos Ai 制药

个人简介:张辉博士刚刚过渡到他作为副总裁的新角色。Entos AI 是一家专注于人工智能驱动的小分子药物发现的生物技术公司。在此之前，张辉博士在辉瑞公司的药物发现部门担任过各种职务，并在过去 14 年中承担越来越多的责任。张博士的工作重点是支持靶标识别、化合物优化和合成孔径雷达(SAR)，在早期药物发现设置中使用各种质谱方法。近期张博士及其团队与 Sciex & Labcyte 的同事合作开发了一种基于声波分配技术和开放孔隙取样界面的新型MS平台，该平台已于2020年商业化。Dr. Hui Zhang just transitioned to his new role as V.P. of discovery analytical at Entos AI, a biotech company focusing on AI driven small drug discovery. Prior to that Hui has held various positions with increasing responsibilities at Pfizer Inc. for the past 14 years at Discovery Science department. Hui’s work focuses on supporting hit identification, compound optimization and SAR, with various mass spectrometry approaches in early drug discovery settings. Hui is particularly specialized with Hit ID, ADME, in vitro assay developments, and bioanalysis applications. Hui is well known in industry for his passion and contribution in high throughput (HT) MS technologies to improve drug discovery efficiencies. At Pfizer he was the pioneer to evaluate and implement various HT bioanalytical platforms including fast multiplexing LC/MS, MALDI, and Affinity Selection MS (ASMS) etc. Recently Hui and his team collaborated with colleagues from Sciex & Labcyte and developed a novel MS platform based on acoustic dispensing technology and open pore sampling interface which was recently commercialized (2020). Dr. Zhang has authored more than 30 peer reviewed scientific publications, and has been an invited speaker/session chair for numerous international conferences and symposiums. He is a recipient for Pfizer Discovery Sciences Innovation Awards and Worldwide R&D Achievement Finalist Awards, and Distinguished Lecture Award by CPSA. 查看更多